Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis

Skeletal Muscle

Volumn 2, Issue 1, 2012, Pages

  Marshall, Amy D ^a,b   Grosveld, Gerard C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alveolar rhabdomyosarcoma; CNR1; CXCR4; FGFR4; IGF2; IRIZIO; MDM2; MET; MiR17 92; N MYC; P Cadherin; P53; PAX3 FOXO1; PAX7 FOXO1; TFAP2B

Indexed keywords

EID: 84873478103     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-2-25     Document Type: Review

References (126)

1. American Cancer Society Rhabdomyosarcoma. http://www.cancer.org/Cancer/Rhabdomyosarcoma/DetailedGuide/rhabdomyosarcoma., American Cancer Society.
2. Punyko JA, Mertens AC, Baker KS, Ness KK, Robison LL, Gurney JG. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 2005, 103:1475-1483. 10.1002/cncr.20929, 15712283.
3. Tonin PN, Scrable H, Shimada H, Cavenee WK. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 1991, 51:5100-5106.
4. Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 2000, 156:399-408. 10.1016/S0002-9440(10)64743-8, 1850049, 10666368.
5. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999, 96:13264-13269. 10.1073/pnas.96.23.13264, 23936, 10557309.
6. Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, et al. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol 2008, 32:1513-1522. 10.1097/PAS.0b013e31817a909a, 18708938.
7. Wexler L, Meyer W, Helman L. Rhabdomyosarcoma and the undifferentiated sarcomas. Principles and Practice of Pediatric Oncology 2006, 971-1001. Philidelphia: Lippincott Williams and Wilkins, Pizzo PA, Poplack D, Fifthth edition.
8. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006, 24:3844-3851. 10.1200/JCO.2005.05.3801, 16921036.
9. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002, 1:97-104.
10. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, Raney RB, Stovall M, Sklar CA, Robison LL, Baker KS. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2005, 44:643-653. 10.1002/pbc.20310, 15700252.
11. Cerveira N, Torres L, Ribeiro FR, Henrique R, Pinto A, Bizarro S, Ferreira AM, Lopes C, Teixeira MR. Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 2005, 163:138-143. 10.1016/j.cancergencyto.2005.06.020, 16337856.
12. Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 2004, 17:660-669. 10.1038/modpathol.3800101, 15098008.
13. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Houghton JA, Green AA. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 1987, 45:148-155. 10.1159/000132446, 3691179.
14. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS, Rovera G, Barr FG. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993, 5:230-235. 10.1038/ng1193-230, 8275086.
15. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, Rauscher FJ. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995, 15:1522-1535. 230376, 7862145.
16. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 1999, 19:594-601. 83917, 9858583.
17. Zhang Y, Schwartz J, Wang C. Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis. Int J Clin Exp Pathol 2009, 2:370-383. 2615594, 19158934.
18. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002, 20:2672-2679. 10.1200/JCO.2002.03.137, 12039929.
19. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994, 54:2869-2872.
20. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 2002, 62:4704-4710.
21. Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, Bridge JA. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010, 49:224-236. 2808450, 19953635.
22. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Buhlmann P, Niggli FK, Schafer BW. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004, 64:5539-5545. 10.1158/0008-5472.CAN-04-0844, 15313887.
23. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 1991, 10:1135-1147. 452767, 2022185.
24. Daston G, Lamar E, Olivier M, Goulding M. Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse. Development 1996, 122:1017-1027.
25. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 2000, 102:777-786. 10.1016/S0092-8674(00)00066-0, 11030621.
26. Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. EMBO J 2004, 23:3430-3439. 10.1038/sj.emboj.7600346, 514519, 15282552.
27. Furuyama T, Nakazawa T, Nakano I, Mori N. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 2000, 349:629-634. 10.1042/0264-6021:3490629, 1221187, 10880363.
28. Misiti S, Koibuchi N, Bei M, Farsetti A, Chin WW. Expression of steroid receptor coactivator-1 mRNA in the developing mouse embryo: a possible role in olfactory epithelium development. Endocrinology 1999, 140:1957-1960. 10.1210/en.140.4.1957, 10098538.
29. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996, 15:3667-3675. 452006, 8670870.
30. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002, 27:352-360. 10.1016/S0968-0004(02)02113-8, 12114024.
31. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003, 17:1681-1692. 10.1210/me.2003-0116, 12805412.
32. Kempf BE, Vogt PK. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. Cell Growth Differ 1999, 10:813-818.
33. Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 1997, 94:8479-8484. 10.1073/pnas.94.16.8479, 22964, 9238002.
34. Belandia B, Parker MG. Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. J Biol Chem 2000, 275:30801-30805.
35. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995, 270:11719-11722. 10.1074/jbc.270.20.11719, 7744814.
36. Miller PJ, Hollenbach AD. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 2007, 1770:1450-1458. 10.1016/j.bbagen.2007.06.016, 2043499, 17698292.
37. Olguin HC, Patzlaff NE, Olwin BB. Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD. J Cell Biochem 2011, 112:1410-1417. 10.1002/jcb.23057, 3071457, 21321994.
38. Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 2012, Epub ahead of print..
39. Charytonowicz E, Matushansky I, Domenech JD, Castillo-Martin M, Ladanyi M, Cordon-Cardo C, Ziman M. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin Transl Oncol 2012, 14:197-206. 10.1007/s12094-012-0784-4, 22374423.
40. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993, 259:1450-1453. 10.1126/science.8383879, 8383879.
41. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol 2010, 28:2126-2128. 10.1200/JCO.2009.27.5339, 20351321.
42. Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol 2010, 28:e587-588. author reply e589-590., 10.1200/JCO.2010.30.5466, 20697086.
43. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009, 174:550-564. 10.2353/ajpath.2009.080631, 2630563, 19147825.
44. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M, Freneaux P, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010, 28:2151-2158. 10.1200/JCO.2009.26.3814, 20351326.
45. Barr FG, Nauta LE, Davis RJ, Schafer BW, Nycum LM, Biegel JA. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 1996, 5:15-21. 10.1093/hmg/5.1.15, 8789435.
46. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008, 68:9583-9588. 10.1158/0008-5472.CAN-07-6178, 2593800, 19047133.
47. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18:2614-2626. 10.1101/gad.1244004, 525542, 15489287.
48. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002, 8:1276-1280. 10.1038/nm787, 12368906.
49. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, Shipley J. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996, 56:3220-3224.
50. Ragazzini P, Gamberi G, Pazzaglia L, Serra M, Magagnoli G, Ponticelli F, Ferrari C, Ghinelli C, Alberghini M, Bertoni F, et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol 2004, 19:401-411.
51. Gordon AT, Brinkschmidt C, Anderson J, Coleman N, Dockhorn-Dworniczak B, Pritchard-Jones K, Shipley J. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2000, 28:220-226. 10.1002/(SICI)1098-2264(200006)28:2<220::AID-GCC11>3.0.CO;2-T, 10825007.
52. Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P, Barr FG. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002, 33:310-321. 10.1002/gcc.10026, 11807989.
53. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 1993, 4:1065-1070.
54. Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look AT. Amplification of the gli gene in childhood sarcomas. Cancer Res 1989, 49:5407-5413.
55. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245. 10.1016/0092-8674(92)90644-R, 1535557.
56. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000, 35:96-103. 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z, 10918230.
57. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992, 52:2243-2247.
58. Leuschner I, Langhans I, Schmitz R, Harms D, Mattke A, Treuner J. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study. Pediatr Dev Pathol 2003, 6:128-136. 10.1007/s10024-001-0097-z, 12574910.
59. Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 1998, 11:1222-1227.
60. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer 1994, 73:2231-2237. 10.1002/1097-0142(19940415)73:8<2231::AID-CNCR2820730832>3.0.CO;2-E, 8156531.
61. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K, Shipley J. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005, 23:880-888. 10.1200/JCO.2005.11.078, 15681534.
62. Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M, Carli M, Rosolen A. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J Pathol 2002, 196:450-458. 10.1002/path.1068, 11920742.
63. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 2011, 17:1463-1473. 10.1158/1078-0432.CCR-10-0091, 3060277, 21220470.
64. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 2007, 67:57-65. 10.1158/0008-5472.CAN-06-1650, 17210683.
65. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007, 6:60. 10.1186/1476-4598-6-60, 2098778, 17894887.
66. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999, 1:340-348. 10.1038/sj.neo.7900052, 1508094, 10935489.
67. Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voute PA, Baas F. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997, 15:1309-1314. 10.1038/sj.onc.1201302, 9315099.
68. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature 1991, 351:153-155. 10.1038/351153a0, 1709450.
69. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, et al. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 1996, 5:783-788. 10.1093/hmg/5.6.783, 8776593.
70. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett 1992, 309:25-28. 10.1016/0014-5793(92)80731-U, 1380925.
71. Picchione F, Pritchard C, Lagutina I, Janke L, Grosveld GC. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS). Carcinogenesis 2011, 32:452-461. 10.1093/carcin/bgq273, 3105580, 21177767.
72. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007, 26:7267-7281. 10.1038/sj.onc.1210525, 17525748.
73. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946. 10.1158/0008-5472.CAN-05-4578, 16849537.
74. Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG, Ladanyi M. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151. 10.1002/path.2170, 17471488.
75. Baer C, Nees M, Breit S, Selle B, Kulozik AE, Schaefer KL, Braun Y, Wai D, Poremba C. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004, 110:687-694. 10.1002/ijc.20171, 15146558.
76. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010, 70:6497-6508. 10.1158/0008-5472.CAN-10-0582, 2922412, 20663909.
77. Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, Pawel BR. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol 2009, 12:275-283. 10.2350/08-03-0434.1, 18788887.
78. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998, 58:5009-5013.
79. De Pitta C, Tombolan L, Albiero G, Sartori F, Romualdi C, Jurman G, Carli M, Furlanello C, Lanfranchi G, Rosolen A. Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 2006, 118:2772-2781. 10.1002/ijc.21698, 16381018.
80. Thuault S, Hayashi S, Lagirand-Cantaloube J, Plutoni C, Comunale F, Delattre O, Relaix F, Gauthier-Rouviere C. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. Oncogene 2012, Epub ahead of print..
81. Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Lae M, Ladanyi M, Barr FG. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 2008, 47:510-520. 10.1002/gcc.20554, 18335505.
82. Begum S, Emami N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005, 24:1860-1872. 10.1038/sj.onc.1208315, 15688035.
83. Oesch S, Walter D, Wachtel M, Pretre K, Salazar M, Guzman M, Velasco G, Schafer BW. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 2009, 8:1838-1845.
84. Marshall AD, Lagutina I, Grosveld GC. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 2011, 71(24):7471-7480. 10.1158/0008-5472.CAN-11-0924, 22037868.
85. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002, 100:2597-2606. 10.1182/blood-2002-01-0031, 12239174.
86. Tomescu O, Xia SJ, Strezlecki D, Bennicelli JL, Ginsberg J, Pawel B, Barr FG. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest 2004, 84:1060-1070. 10.1038/labinvest.3700125, 15184910.
87. Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M, Ratajczak MZ. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010, 8:1-14. 10.1158/1541-7786.MCR-09-0259, 2943743, 20068066.
88. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001, 7:673-679. 10.1038/89044, 1282521, 11385503.
89. Marshall AD, Van Der Ent MA, Grosveld GC. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Mol Carcinog 2012, 51(10):807-815. 10.1002/mc.20848, 21882254.
90. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, Yagyu S, Tsubai-Shimizu S, Miyachi M, Iehara T, Hosoi H. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008, 365:568-574. 10.1016/j.bbrc.2007.11.017, 18022385.
91. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006, 66:4742-4749. 10.1158/0008-5472.CAN-05-4292, 16651427.
92. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998, 58:3542-3546.
93. Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Astolfi A, et al. Antitumor activity of sustained N-Myc reduction in Rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 2011,
94. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande-Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804. 10.1126/science.1846706, 1846706.
95. Brand-Saberi B, Muller TS, Wilting J, Christ B, Birchmeier C. Scatter factor/hepatocyte growth factor (SF/HGF) induces emigration of myogenic cells at interlimb level in vivo. Dev Biol 1996, 179:303-308. 10.1006/dbio.1996.0260, 8873773.
96. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771. 10.1038/376768a0, 7651534.
97. Epstein JA, Shapiro DN, Cheng J, Lam PY, Maas RL. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 1996, 93:4213-4218. 10.1073/pnas.93.9.4213, 39514, 8633043.
98. Lukasiewicz E, Miekus K, Kijowski J, Drabik G, Wilusz M, Bobis-Wozowicz S, Majka M. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling. Folia Histochem Cytobiol 2009, 47:485-489.
99. Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003, 63:7926-7935.
100. Diomedi-Camassei F, McDowell HP, De Ioris MA, Uccini S, Altavista P, Raschella G, Vitali R, Mannarino O, De Sio L, Cozzi DA, et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res 2008, 14:4119-4127. 10.1158/1078-0432.CCR-07-4446, 18593989.
101. Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, Rando TA, Weissman IL, Wagers AJ. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004, 119:543-554. 10.1016/j.cell.2004.10.021, 15537543.
102. D'Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, Baggiolini M, Moser B. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997, 27:1788-1793. 10.1002/eji.1830270729, 9247593.
103. Strahm B, Durbin AD, Sexsmith E, Malkin D. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2008, 25:1-10.
104. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4225. 10.1046/j.1460-9568.1999.00847.x, 10594647.
105. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110. 10.1016/j.bbrc.2007.09.099, 17935697.
106. Lagha M, Sato T, Bajard L, Daubas P, Esner M, Montarras D, Relaix F, Buckingham M. Regulation of skeletal muscle stem cell behavior by Pax3 and Pax7. Cold Spring Harb Symp Quant Biol 2008, 73:307-315. 10.1101/sqb.2008.73.006, 19022756.
107. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012, 18(14):3780-3790. 10.1158/1078-0432.CCR-10-3063, 22648271.
108. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009, 119:3395-3407. 2769177, 19809159.
109. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, Houghton PJ. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 1987, 47:4501-4507.
110. Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, Sartori F, Follo MY, Oliver N, De Giovanni C, Nanni P, Lollini PL. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 2004, 64:1730-1736. 10.1158/0008-5472.CAN-3502-02, 14996733.
111. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007, 49:928-940. 10.1002/pbc.21078, 17066459.
112. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011, 56:239-249. 10.1002/pbc.22801, 3005554, 20922763.
113. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583. 10.1158/1078-0432.CCR-07-5090, 18628472.
114. Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol 2009, 175:2600-2608. 10.2353/ajpath.2009.090192, 2789624, 19893043.
115. Scuoppo C, Riess I, Schmitt-Ney M, Allegra P, Forni PE, Bersani F, Taulli R, Accornero P, Crepaldi T, Ponzetto C. The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Exp Cell Res 2007, 313:2308-2317. 10.1016/j.yexcr.2007.02.037, 17490646.
116. Xia SJ, Barr FG. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 2004, 23:6864-6871. 10.1038/sj.onc.1207850, 15286710.
117. Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H, Anderson MJ. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008, 68:6587-6597. 10.1158/0008-5472.CAN-08-0859, 18701482.
118. Roeb W, Boyer A, Cavenee WK, Arden KC. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA 2007, 104:18085-18090. 10.1073/pnas.0708910104, 2084300, 17986608.
119. Pressey JG, Pressey CS, Robinson G, Herring R, Wilson L, Kelly DR, Kim H. 2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma. J Proteome Res 2011, 10:624-636. 10.1021/pr1008493, 3071502, 21110518.
120. Lagutina I, Conway SJ, Sublett J, Grosveld GC. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol 2002, 22:7204-7216. 10.1128/MCB.22.20.7204-7216.2002, 139793, 12242297.
121. Finckenstein FG, Davicioni E, Osborn KG, Cavenee WK, Arden KC, Anderson MJ. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Res 2006, 15:595-614. 10.1007/s11248-006-9011-9, 16952014.
122. Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA 2001, 98:1589-1594. 10.1073/pnas.98.4.1589, 29301, 11171995.
123. Galindo RL, Allport JA, Olson EN. A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci USA 2006, 103:13439-13444. 10.1073/pnas.0605926103, 1569182, 16938866.
124. Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN, Hansen MS, Blandford MC, McCleish AT, Rubin BP, et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J 2009, 23:2681-2690. 10.1096/fj.08-128116, 2717773, 19332644.
125. Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res 2005, 65:7530-7532.
126. Osborne CS, Chakalova L, Mitchell JA, Horton A, Wood AL, Bolland DJ, Corcoran AE, Fraser P. Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. PLoS Biol 2007, 5:e192. 10.1371/journal.pbio.0050192, 1945077, 17622196.